NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

NCTN 在 Dana-Farber/Partners Cancer Care 的主要学术参与网站

• 批准号: 9439701
• 负责人: Harold John Burstein
• 金额: $ 130.22万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-19 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9439701
• 关键词: Adherence; Adult; Awareness; Benchmarking; Cancer Center; Caring; Clinical; Clinical Investigator; Clinical Research; Clinical Treatment; Clinical Trials; Clinical Trials Cooperative Group; Clinical Trials Network; Collaborations; Committee Membership; Conduct Clinical Trials; Dana-Farber Cancer Institute; Development; Discipline; Disease; Doctor of Medicine; Doctor of Philosophy; Ensure; Faculty; Funding; Future; General Hospitals; Generations; Goals; Grant; Hospitals; Image; Institution; Joint Ventures; Knowledge; Lead; Leadership; Malignant Neoplasms; Massachusetts; Mentors; Modality; Modeling; Monitor; National Clinical Trials Network; Operations Research; Patients; Performance; Positioning Attribute; Principal Investigator; Protocols documentation; Quality of life; Research Infrastructure; Research Personnel; Role; Site; Societies; System; Time; Training; Translations; Woman; Work; base; cancer care; cancer clinical trial; clinical implementation; cohesion; experience; high standard; improved; investigator training; novel; oncology; organizational structure; programs; public health relevance; trial design; tumor

DESCRIPTION (provided by applicant): The overall goal of this application is for Farber/Partners Cancer Care (DF/PCC) to serve as a Lead Academic Participating Site in NCTN and become a leading contributor to NCTN activities. DF/PCC is a joint venture focused on conducting clinical trials and clinical investigator training by across three Harvard- affiliate institutions: Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital. All are national leaders in cancer clinical research and work cohesively through a well- established unified clinical trials program. Specific aims are: provide leaders to develop and conduct clinical trials, and support NCTN through substantial, robust accrual. While DF/PCC will have as its primary affiliation the Alliance Network Group, faculties will continue their strong historical relationships with a variety of Network Groups. Through a multiple PD/PI model, an engaged interdisciplinary faculty, and a strong operational infrastructure, DF/PCC will provide senior scientific input to trial development trials; identify novel trials to be brought to NCTN; prioritize NCTN trials within our clinical trials portfolio; assure timely activation; provid training and mentoring; distribute funding fairly; and ensure adherence at participating sites. DF/PCC will impact NCTN, which will define new standards of care for adult patients with cancer through 1) scientific leadership in the Steering Committees; 2) participation in CIRB; 3) executive and committee leadership and membership; 4) executive and committee leadership, as well as committee membership; 5) serving as affiliated PIs; 6) leadership in accrual; and 7) training a new generation to participate in the national clinical trials network enterprise.

描述（由申请人提供）：本申请的总体目标是Farber/Partners Cancer Care（DF/PCC）作为NCTN的主要学术参与站点，并成为NCTN活动的主要贡献者。DF/PCC是一家合资企业，专注于在三个哈佛附属机构进行临床试验和临床研究者培训：达纳法伯癌症研究所，布里格姆妇女医院和马萨诸塞州总医院。他们都是癌症临床研究的国家领导者，并通过一个完善的统一临床试验计划团结一致地工作。具体目标是：提供领导者开发和进行临床试验，并通过大量的，强大的应计支持NCTN。虽然DF/PCC将作为其主要附属机构的联盟网络集团，院系将继续与各种网络集团的强大的历史关系。通过多个PD/PI模型，参与的跨学科教师和强大的运营基础设施，DF/PCC将为试验开发试验提供高级科学投入;确定新的试验， NCTN;在我们的临床试验组合中优先考虑NCTN试验;确保及时激活;提供培训和指导;公平分配资金;并确保参与研究中心的依从性。DF/PCC将影响NCTN，NCTN将通过1）指导委员会的科学领导; 2）参与CIRB; 3）执行和委员会领导和成员; 4）执行和委员会领导以及委员会成员; 5）担任附属PI; 6）应计领导;培养新一代参与国家临床试验网络的企业。